Global Leading Market Research Publisher QYResearch announces the release of its latest report “Biological Inactivated Vaccine – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″.
Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart):
https://www.qyresearch.com/reports/4794852/biological-inactivated-vaccine
To Pharmaceutical Executives, Public Health Officials, and Vaccine Investors:
If your organization manufactures or procures vaccines for infectious disease prevention, you face a persistent challenge: balancing vaccine safety (risk of causing disease in recipients) with immunogenicity (ability to induce protective immunity). Live-attenuated vaccines offer strong immunity but pose risks to immunocompromised individuals. The solution lies in biological inactivated vaccines —a type of vaccine that uses physical or chemical methods (such as heat treatment, formaldehyde, β-propiolactone, etc.) to completely kill pathogenic microorganisms (viruses, bacteria, etc.), making them lose their infectivity and pathogenicity while retaining their main antigenic structure to induce the body to produce a specific immune response. According to QYResearch’s newly released market forecast, the global biological inactivated vaccine market was valued at US$892 million in 2024 and is projected to reach US$1,263 million by 2031, growing at a compound annual growth rate (CAGR) of 5.1 percent during the 2025-2031 forecast period. This steady growth reflects the continued essential role of inactivated vaccines in preventing hepatitis A, polio (IPV), rabies, COVID-19 (inactivated whole-virus vaccines), influenza (some formulations), and other infectious diseases, particularly in immunocompromised populations where live vaccines are contraindicated.
1. Product Definition: Killed Pathogens for Safe Immunization
Biological inactivated vaccines refer to a type of vaccine that uses physical or chemical methods (such as heat treatment, formaldehyde, β-propiolactone, etc.) to completely kill pathogenic microorganisms (such as viruses, bacteria, etc.), making them lose their infectivity and pathogenicity, while retaining their main antigenic structure to induce the body to produce a specific immune response. This type of vaccine is highly safe and suitable for people with weak immunity (e.g., HIV patients, organ transplant recipients, chemotherapy patients, elderly individuals with waning immunity). It is widely used to prevent hepatitis A, polio, rabies, new coronavirus (COVID-19), and other infectious diseases.
The inactivation process typically involves growing the pathogen in cell culture or embryonated eggs, harvesting and purifying the pathogen, then treating with inactivating agents (formaldehyde, β-propiolactone, heat, or UV radiation) under controlled conditions to ensure complete loss of infectivity while preserving antigenic structure. Inactivated vaccines cannot replicate in the host, so multiple doses (primary series) and booster doses are often required to achieve and maintain protective immunity, as they do not provide the sustained antigen exposure that live vaccines do.
The market is segmented by pathogen type into inactivated virus vaccine (the larger segment, approximately 80-85 percent of revenue, including hepatitis A, inactivated polio vaccine (IPV), rabies, COVID-19, influenza (inactivated), Japanese encephalitis (inactivated), tick-borne encephalitis) and inactivated bacterial vaccine (including whole-cell pertussis (wP), typhoid (inactivated), cholera (inactivated), plague). Inactivated virus vaccines dominate due to the high burden of viral diseases and the safety advantages of inactivated vaccines for certain viruses (polio, rabies).
By application, the market serves humans (the largest segment, approximately 90-95 percent of revenue, including routine childhood immunization, travel vaccines, occupational vaccines (rabies for veterinarians), and pandemic response) and animals (veterinary vaccines for livestock and companion animals, including rabies, foot-and-mouth disease (inactivated), and other veterinary inactivated vaccines). The human segment dominates, but the animal segment is growing steadily (5-6 percent CAGR) driven by livestock disease control programs.
2. Key Market Drivers: Inactivated Polio Vaccine (IPV) Mandates, Rabies Endemicity, and COVID-19 Legacy
The biological inactivated vaccine market is driven by three primary forces: the global switch from oral polio vaccine (OPV) to inactivated polio vaccine (IPV) in routine immunization, the continued high demand for rabies vaccines (both human and veterinary), and the legacy of COVID-19 inactivated whole-virus vaccines (Sinovac, Sinopharm, Bharat Biotech).
A. Global Switch from OPV to IPV
Oral polio vaccine (OPV, live-attenuated) has been the cornerstone of polio eradication efforts, but OPV carries a rare risk of vaccine-derived poliovirus (VDPV) outbreaks. Inactivated polio vaccine (IPV, injected) does not carry this risk. The Global Polio Eradication Initiative (GPEI) has recommended that countries introduce IPV into routine immunization schedules and eventually phase out OPV. According to WHO 2025 data , 80 percent of countries have introduced IPV into routine immunization, with continued expansion in lower-income countries. IPV requires 2-4 doses per child (depending on schedule), representing 200-400 million doses annually for global birth cohorts (approximately 100 million newborns per year). A user case from a national immunization program in Southeast Asia (documented in Q1 2025) reported that switching from OPV to IPV increased the country’s inactivated vaccine procurement from 5 million doses to 40 million doses annually (8-fold increase), as IPV is an inactivated vaccine requiring multiple doses per child, whereas OPV was a live vaccine.
B. Rabies Endemicity and Post-Exposure Prophylaxis
Rabies is a viral zoonotic disease with near 100 percent fatality once symptoms appear. Rabies vaccines (inactivated) are used for pre-exposure prophylaxis (veterinarians, animal handlers, travelers to endemic areas) and post-exposure prophylaxis (PEP) after animal bites. According to WHO 2025 data , rabies causes approximately 59,000 human deaths annually, primarily in Asia and Africa. Post-exposure prophylaxis requires 3-5 doses of rabies vaccine plus rabies immunoglobulin for severe exposures. Global rabies vaccine demand is estimated at 50-100 million doses annually for human use, plus additional doses for veterinary use (dog rabies vaccination campaigns to interrupt transmission). A user case from a rabies-endemic country in South Asia (documented in Q4 2024) reported that the government procured 10 million human rabies vaccine doses annually for free distribution to bite victims, representing US$50-100 million in annual vaccine expenditure, with the vaccine being an inactivated vaccine (rabies virus grown in cell culture, then β-propiolactone inactivated).
C. COVID-19 Inactivated Whole-Virus Vaccines
Several COVID-19 vaccines are inactivated whole-virus vaccines: Sinovac (CoronaVac) , Sinopharm (BBIBP-CorV) , Bharat Biotech (Covaxin) . These vaccines were widely used in China, India, Brazil, Indonesia, and many other countries. According to Our World in Data 2025 data , over 3 billion doses of inactivated COVID-19 vaccines were administered globally (approximately 30-40 percent of total COVID-19 vaccine doses). While COVID-19 vaccine demand has declined from pandemic peaks, ongoing vaccination (booster doses, annual campaigns) will sustain demand for inactivated vaccines. Additionally, the manufacturing capacity built for COVID-19 inactivated vaccines (cell culture, inactivation, purification, formulation) can be repurposed for other inactivated vaccines (influenza, polio, rabies), increasing supply and reducing costs.
Exclusive Analyst Observation (Q2 2025 Data): The biological inactivated vaccine market is characterized by a significant geographic concentration of manufacturing. China is the world’s largest producer and consumer of inactivated vaccines, driven by Sinovac (CoronaVac, enterovirus 71 vaccine for hand-foot-mouth disease), Sinopharm (COVID-19, IPV, rabies), and other Chinese manufacturers (Kangtai Biological, Zhifei Biological, AIM Vaccine). India is also a major producer, with Serum Institute of India (SII) producing inactivated polio vaccine (IPV) and other inactivated vaccines, and Bharat Biotech producing Covaxin and other inactivated vaccines. Europe and North America have reduced their inactivated vaccine manufacturing capacity over time, shifting to newer vaccine technologies (mRNA, viral vector, recombinant protein). However, inactivated vaccines remain essential for certain applications where newer technologies are not available or not cost-effective: IPV (polio), rabies (post-exposure prophylaxis), and hepatitis A.
3. Competitive Landscape: Global Vaccine Giants and Emerging Market Manufacturers
Based on QYResearch 2024-2025 market data and confirmed by company annual reports, the biological inactivated vaccine market features global vaccine giants (with diverse vaccine portfolios including inactivated vaccines) and emerging market manufacturers (specializing in inactivated vaccines for local and regional markets).
Global Vaccine Giants: Sanofi (France, IPV, rabies, influenza inactivated), GSK (UK, hepatitis A, IPV combination vaccines), Merck (US, IPV combination vaccines), Pfizer (US, IPV combination vaccines), Valneva (France, inactivated COVID-19, chikungunya), Takeda (Japan, inactivated Japanese encephalitis, dengue), and Emergent BioSolutions (US, anthrax vaccine (inactivated), other biodefense vaccines).
Emerging Market Manufacturers (China): Sinovac (China, inactivated COVID-19, enterovirus 71, hepatitis A), China Biotechnology (Sinopharm, inactivated COVID-19, IPV, rabies), Kangtai Biological (China), Zhifei Biological (China), and AIM Vaccine (China).
Emerging Market Manufacturers (India): Serum Institute of India (SII) (India, IPV), Bharat Biotech (India, inactivated COVID-19, rabies, typhoid), Biological E (India), and others.
Other Regional Players: KM Biologics (Japan), Baxter (US), Bio Farma (Indonesia), IVAC (Vietnam), Sinergium Biotech (Argentina).
4. Market Outlook 2025-2031 and Strategic Recommendations
Based on QYResearch forecast models, the global biological inactivated vaccine market will reach US$1,263 million by 2031 at a CAGR of 5.1 percent.
For public health officials: Maintain IPV in routine immunization schedules as the safe alternative to OPV. Ensure adequate rabies vaccine supply for post-exposure prophylaxis in endemic countries. Consider inactivated influenza vaccines for immunocompromised individuals (where live attenuated influenza vaccine (LAIV) is contraindicated).
For vaccine manufacturers: Invest in cell culture-based inactivated vaccine platforms (Vero cells, MDCK cells) for rapid response to emerging pathogens. Optimize inactivation processes (formaldehyde, β-propiolactone, heat) to maximize immunogenicity while ensuring safety. Explore combination inactivated vaccines (e.g., DTaP-IPV-Hib-HepB) to reduce number of injections.
For investors: Chinese manufacturers (Sinovac, Sinopharm, Kangtai, Zhifei) are positioned for steady domestic growth. Indian manufacturers (SII, Bharat Biotech) serve global markets (UNICEF, PAHO, Gavi). Global giants (Sanofi, GSK, Merck, Pfizer) have diversified portfolios but face competition from lower-cost emerging market manufacturers.
Key risks to monitor include the potential phase-out of certain inactivated vaccines as newer technologies (mRNA, viral vector) offer superior immunogenicity (fewer doses, longer protection), price pressure from low-cost generic inactivated vaccines (particularly for rabies and IPV), and manufacturing capacity constraints for cell culture-based inactivated vaccines (cell culture is capital-intensive).
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
